Ownership and insider activity for Evogene Ltd. (EVGN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform.
Price
| Price | $0.50 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | IL |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-04 | Tarcic Gabi | P-Purchase | 1,129 | $677 |
| 2026-08-11 | RECANATI LEON | P-Purchase | 460,000 | $292K |
| 2026-08-04 | RECANATI LEON | P-Purchase | 800,000 | $400K |
| 2026-02-03 | Ravzin Polina | 3,000 | $37K | |
| 2026-04-01 | Ravzin Polina | 1,500 | $12K | |
| 2026-04-01 | Ravzin Polina | 6,000 | $9K | |
| 2026-04-01 | Ravzin Polina | 9,500 | $9K | |
| 2026-03-18 | RECANATI LEON | |||
| 2020-06-11 | RECANATI LEON | 250 | $18K | |
| 2021-06-11 | RECANATI LEON | 250 | $14K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.2M | $3.4M | $5.8M | $34.7M | $46.2M | $32.3M | $29.0M | $20.8M | $15.3M | $13.0M |
| Short-term Investments | $84.9M | $68.3M | $48.7M | $12.1M | $2.0M | $21.5M | $6.4M | $10.3M | $10000 | 0 |
| Receivables | $1.2M | $813000 | $746000 | $1.2M | $2.2M | $1.2M | $803000 | $804000 | $1.5M | $1.4M |
| Inventory | 0 | 0 | 0 | 0 | 0 | $92000 | $566000 | $76000 | $1.8M | $210000 |
| Total Current Assets | $89.5M | $72.8M | $55.5M | $49.0M | $51.8M | $56.9M | $37.8M | $34.5M | $21.6M | $15.6M |
| Property, Plant & Equipment | $6.5M | $4.8M | $3.2M | $5.3M | $3.9M | $4.2M | $4.1M | $3.4M | $4.3M | $2.6M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | $17.1M | $16.1M | $15.2M | $14.1M | $13.2M | $12.2M | 0 |
| Total Assets | $96.0M | $77.6M | $58.7M | $71.4M | $71.9M | $76.3M | $56.1M | $51.1M | $39.9M | $20.0M |
| Accounts Payable | $1.3M | $1.1M | $1.0M | $1.0M | $863000 | $1.5M | $1.0M | $1.8M | $1.2M | $639000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $10.4M | 0 |
| Total Current Liabilities | $5.2M | $4.7M | $5.4M | $5.7M | $9.7M | $6.9M | $5.6M | $6.9M | $18.7M | $3.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $10.1M | $10.4M | 0 | 0 |
| Total Liabilities | $8.7M | $8.2M | $8.4M | $11.1M | $15.0M | $12.9M | $21.3M | $22.4M | $25.0M | $8.1M |
| Retained Earnings | -$96.2M | -$117.0M | -$137.8M | -$155.9M | -$179.3M | -$207.1M | -$233.7M | -$257.6M | -$274.1M | -$282.6M |
| Total Equity | $87.3M | $69.4M | $50.1M | $50.1M | $46.0M | $53.7M | $27.9M | $12.1M | -$1.5M | -$82000 |
| Total Debt | 0 | 0 | 0 | $3.0M | $2.4M | $2.7M | $11.9M | $11.5M | $12.9M | $2.2M |
| Net Debt | -$88.1M | -$71.8M | -$54.5M | -$43.9M | -$45.8M | -$51.2M | -$23.4M | -$19.6M | -$2.4M | -$10.8M |
| Working Capital | $84.3M | $68.1M | $50.1M | $43.3M | $42.1M | $50.0M | $32.1M | $27.5M | $2.9M | $12.2M |
Financial Health
| Debt / Equity | -0.64 |
| Current Ratio | 3.57 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -20.48 |
Profitability
| Return on Equity | 766.01% |
| Return on Invested Capital | -121.41% |
| Return on Assets | -68.20% |
| Gross Margin | -14.16% |
| Operating Margin | -1020.35% |
| Net Margin | -696.26% |
Related companies: AEON · BOLT · CING · CLRB · COCP · DWTX · GLTO
Explore sector: Healthcare · Biotechnology
More sections of EVGN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks